Initiation of Contact and Asthmatic Hypersensitivity

接触的开始和哮喘过敏

基本信息

  • 批准号:
    7023890
  • 负责人:
  • 金额:
    $ 35.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-03-01 至 2009-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We will study the "initiation" of the elicitation of T cell mediated immunity in vivo. We have discovered that the initiation of elicitation is due to a series of processes. We postulate that these processes begin within hours after sensitization. We postulate that within 1-hr of immunization there is activation of Valpha14+ Jalpha18+ CD1d-restricted NKT cells. The NKT cells produce IL-4 to co-activate the Beta-1 Beta cell subset to produce initiating IgM antibodies. This, leads via local complement C5a activation of mast cells, to the local recruitment of effector T cells to the site of Ag challenge. These initiating processes occur in the murine model of allergic contact dermatitis, and in a related model of occupational asthma involving hapten elicitation of airway hyperreactivity (AHR) within 1-day of immunization. AHR similarly is postulated to depend on an early process mediated by NKT cell stimulated Beta-1 cell mediated C5a generation. Our focus in this proposal is the induction of CS-initiating Beta-1 cells. We propose this is due to prior rapid activation of NKT cells, perhaps via release endogenous glycolipid antigens, within hours post-contact immunization, to produce IL-4 that co-activates the Beta-1 cell, to produce the initiating IgM antibodies. Taken together, these studies extend the study of CS-initiation to induction of the mediating Beta-1 cells, potentially activated via NKT cell IL-4, and extend these concepts to mouse models of occupational medicine. Specific Aim #1: We will determine whether NKT cells are essential in CS, how they are activated, and if the NKT cells function in the initiation of CS by potentially producing IL-4. Specific Aim #2: We will determine if and how Beta-1 cells are activated by IL-4 early in the induction of CS, and whether IL-4, acting via STAT-6 signaling is essential, and how the Beta-1 cells may possibly migrate to lymph nodes and then to produce circulating CS-initiating IgM antibodies by only 1-day post-immunization. Specific Aim #3: In a hapten induced murine model of occupational asthma, we will determine the potential role of NKT cells in the production of B-1 cell derived IgM antibodies, that mediate C5a-dependent airway hyperreactivity (AHR); just 1-day post-immunization; and the mechanisms of the induced AHR.
描述(由申请人提供):我们将在体内研究T细胞介导的免疫激发的“起始”。我们发现,引发是由于一系列的过程。我们假设这些过程在致敏后几小时内开始。我们假设在免疫后1小时内,存在Valpha 14 + Jalpha 18 + CD 1d限制性NKT细胞的活化。NKT细胞产生IL-4以共激活β-1 β细胞亚群以产生起始IgM抗体。这通过肥大细胞的局部补体C5 a活化导致效应T细胞局部募集到Ag攻击位点。这些起始过程发生在过敏性接触性皮炎的鼠模型中,以及在免疫后1天内涉及半抗原诱发气道高反应性(AHR)的职业性哮喘的相关模型中。类似地,假定AHR依赖于由NKT细胞刺激的β-1细胞介导的C5 a生成介导的早期过程。我们在这个建议中的重点是诱导CS起始β-1细胞。我们认为这是由于NKT细胞在接触免疫后数小时内快速活化,可能通过释放内源性糖脂抗原产生IL-4,IL-4共活化β-1细胞,产生起始IgM抗体。总之,这些研究将CS启动的研究扩展到介导β-1细胞的诱导,可能通过NKT细胞IL-4激活,并将这些概念扩展到职业医学的小鼠模型。 具体目标1:我们将确定NKT细胞是否在CS中是必不可少的,它们是如何被激活的,以及NKT细胞是否通过潜在地产生IL-4而在CS的起始中起作用。 具体目标#2:我们将确定β-1细胞是否以及如何在CS诱导早期被IL-4激活,以及通过STAT-6信号传导起作用的IL-4是否是必需的,以及β-1细胞如何可能迁移到淋巴结,然后仅在免疫后1天产生循环CS起始IgM抗体。 具体目标#3:在半抗原诱导的职业性哮喘小鼠模型中,我们将确定NKT细胞在产生B-1细胞衍生的IgM抗体中的潜在作用,该IgM抗体介导C5 α依赖性气道高反应性(AHR);仅在免疫后1天;以及诱导的AHR的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PHILIP William ASKENASE其他文献

PHILIP William ASKENASE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PHILIP William ASKENASE', 18)}}的其他基金

The Role of AID in Contact Sensitivity
AID 在接触敏感性中的作用
  • 批准号:
    7847588
  • 财政年份:
    2009
  • 资助金额:
    $ 35.92万
  • 项目类别:
The Role of AID in Contact Sensitivity
AID 在接触敏感性中的作用
  • 批准号:
    7347659
  • 财政年份:
    2009
  • 资助金额:
    $ 35.92万
  • 项目类别:
Initiation of Contact and Asthmatic Hypersensitivity
接触的开始和哮喘过敏
  • 批准号:
    7183609
  • 财政年份:
    2004
  • 资助金额:
    $ 35.92万
  • 项目类别:
Initiation of Contact and Asthmatic Hypersensitivity
接触的开始和哮喘过敏
  • 批准号:
    7367191
  • 财政年份:
    2004
  • 资助金额:
    $ 35.92万
  • 项目类别:
Initiation of Contact and Asthmatic Hypersensitivity
接触的开始和哮喘过敏
  • 批准号:
    6861027
  • 财政年份:
    2004
  • 资助金额:
    $ 35.92万
  • 项目类别:
Initiation of Contact and Asthmatic Hypersensitivity
接触的开始和哮喘过敏
  • 批准号:
    6759076
  • 财政年份:
    2004
  • 资助金额:
    $ 35.92万
  • 项目类别:
B CELLS AND ACQUIRED T CELL IMMUNITY
B 细胞和获得性 T 细胞免疫
  • 批准号:
    2902521
  • 财政年份:
    1999
  • 资助金额:
    $ 35.92万
  • 项目类别:
INITIATOR T CELLS IN DELAYED-TYPE HYPERSENSITIVITY
迟发型超敏反应中的启动 T 细胞
  • 批准号:
    3140567
  • 财政年份:
    1989
  • 资助金额:
    $ 35.92万
  • 项目类别:
INITIATOR CELLS IN DELAYED-TYPE HYPERSENSITIVITY
迟发型超敏反应的起始细胞
  • 批准号:
    2063492
  • 财政年份:
    1989
  • 资助金额:
    $ 35.92万
  • 项目类别:
INITIATOR CELLS IN DELAYED-TYPE HYPERSENSITIVITY
迟发型超敏反应的起始细胞
  • 批准号:
    2063491
  • 财政年份:
    1989
  • 资助金额:
    $ 35.92万
  • 项目类别:

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 35.92万
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    $ 35.92万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 35.92万
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    $ 35.92万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 35.92万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 35.92万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 35.92万
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    $ 35.92万
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    $ 35.92万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    $ 35.92万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了